New Zealand - English - Medsafe (Medicines Safety Authority)

actavis new zealand limited - ipratropium bromide monohydrate 0.0261%{relative} equivalent to ipratropium 0.025% w/v - solution for inhalation - 250 mcg/ml - active: ipratropium bromide monohydrate 0.0261%{relative} equivalent to ipratropium 0.025% w/v excipient: hydrochloric acid sodium chloride water for injection - ipratropium bromide is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema and when used concomitantly with inhaled beta-agonists, for asthma.

New Zealand - English - Medsafe (Medicines Safety Authority)

actavis new zealand limited - ipratropium bromide monohydrate 0.0261%{relative} equivalent to ipratropium 0.025% w/v - solution for inhalation - 0.5 mg/2ml - active: ipratropium bromide monohydrate 0.0261%{relative} equivalent to ipratropium 0.025% w/v excipient: hydrochloric acid sodium chloride water for injection - ipratropium bromide is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema and when used concomitantly with inhaled beta-agonists, for asthma.

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa inc - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) - ipratropium bromide anhydrous 0.5 mg in 3 ml

United States - English - NLM (National Library of Medicine)

cipla usa inc. - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e), ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) - albuterol 2.5 mg in 3 ml - ipratropium bromide and albuterol sulfate inhalation solution is indicated for the treatment of bronchospasm associated with copd in patients requiring more than one bronchodilator. ipratropium bromide and albuterol sulfate inhalation solution is contraindicated in patients with a history of hypersensitivity to any of its components, or to atropine and its derivatives.

United States - English - NLM (National Library of Medicine)

boehringer ingelheim pharmaceuticals inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul), albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - ipratropium bromide anhydrous 20 ug - combivent respimat is a combination of ipratropium bromide (an anticholinergic agent) and albuterol sulfate (a beta2 -adrenergic agonist) indicated for use in patients with chronic obstructive pulmonary disease (copd) on a regular aerosol bronchodilator who continue to have evidence of bronchospasm and who require a second bronchodilator. combivent respimat is contraindicated in the following conditions [see warnings and precautions (5.6) ]: - hypersensitivity to any of the ingredients in combivent respimat - hypersensitivity to atropine or any of its derivatives risk summary there are no randomized clinical studies of combivent respimat, or its individual components, ipratropium bromide and albuterol sulfate, in pregnant women. ipratropium is negligibly absorbed systemically following oral inhalation; therefore, maternal use is not expected to result in fetal exposure to the drug [see clinical pharmacology (12.3)] . published literature, including cohort studies, case control studies and case series, over s

United States - English - NLM (National Library of Medicine)

ritedose pharmaceuticals, llc - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e), ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) - albuterol 2.5 mg in 3 ml - ipratropium bromide and albuterol sulfate inhalation solution is indicated for the treatment of bronchospasm associated with copd in patients requiring more than one bronchodilator. ipratropium bromide and albuterol sulfate inhalation solution is contraindicated in patients with a history of hypersensitivity to any of its components, or to atropine and its derivatives.

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) - ipratropium bromide anhydrous 0.5 mg in 3 ml

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - ipratropium bromide monohydrate, quantity: 522 microgram (equivalent: ipratropium bromide, qty 500 microgram) - inhalation, conventional - excipient ingredients: sodium chloride; water for injections; hydrochloric acid - for moderate asthma attacks; chronic forms of asthma; asthma in patients with diminished cardiac reserve; chronic obstructive bronchitis with bronchospasm; bronchospasm during or after surgery; use during assisted ventilation with a respirator.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - ipratropium bromide monohydrate, quantity: 261 microgram (equivalent: ipratropium bromide, qty 250 microgram) - inhalation, conventional - excipient ingredients: water for injections; hydrochloric acid; sodium chloride - for moderate asthma attacks; chronic forms of asthma; asthma in patients with diminished cardiac reserve; chronic obstructive bronchitis with bronchospasm; bronchospasm during or after surgery; use during assisted ventilation with a respirator.

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - ipratropium bromide monohydrate, quantity: 0.261 mg/ml (equivalent: ipratropium bromide, qty 0.25 mg/ml) - inhalation, conventional - excipient ingredients: purified water; benzalkonium chloride; sodium chloride; hydrochloric acid; disodium edetate - moderate asthmatic attacks; chronic forms of asthma; asthma in patients with diminished cardiac reserve; chronic obstructive bronchitis with bronchospasm; bronchospasm during or after surgery, use during assisted ventilation with a respirator. administration of atrovent via a nebuliser is intended for those patients who cannot use a metered dose aerosol.